🇺🇸 FDA

Intelligence Platform

Patents

Browse 822 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12018298

PH20 polypeptide variants, formulations and uses thereof

HALOZYME, INC. · Granted Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12011437

Roflumilast formulations with an improved pharmacokinetic profile

ARCUTIS BIOTHERAPEUTICS, INC. · Granted Tue Jun 18 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 13 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12005060

Ophthalmic formulations of methotrexate

Aldeyra Therapeutics, Inc. · Granted Tue Jun 11 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12005051

Topical roflumilast formulation having improved delivery and plasma half life

ARCUTIS BIOTHERAPEUTICS, INC. · Granted Tue Jun 11 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12005139

Ophthalmic formulations and related methods

ETERNATEAR, INC. · Granted Tue Jun 11 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12005052

Topical roflumilast formulation having improved delivery and plasma half-life

ARCUTIS BIOTHERAPEUTICS, INC. · Granted Tue Jun 11 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12005061

Ophthalmic formulations of methotrexate

Aldeyra Therapeutics, Inc. · Granted Tue Jun 11 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11998639

Formulations of (R)-2-amino-3-phenylpropyl carbamate

AXSOME MALTA LTD. · Granted Tue Jun 04 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11998604

Therapeutic uses for sodium thiosulfate formulations

Fennec Pharmaceuticals, Inc. · Granted Tue Jun 04 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11992530

Therapeutic uses for sodium thiosulfate and formulations

Fennec Pharn ceuticals Inc. · Granted Tue May 28 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 23 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11969501

Auris formulations for treating otic diseases and conditions

The Regents of the University of California · Granted Tue Apr 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11964047

Ophthalmic formulations and related methods

ETERNATEAR, INC. · Granted Tue Apr 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11964018

Therapeutic uses for sodium thiosulfate formulations

Fennec Pharmaceuticals, Inc. · Granted Tue Apr 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11957740

Complex of botulinum neurotoxin E and its binding protein as a formulation with enhanced p

Prime Bio, Inc. · Granted Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11957674

Formulations of a somatostatin modulator

CRINETICS PHARMACEUTICALS, INC. · Granted Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11957754

Clinical formulations

Astellas Institute for Regenerative Medicine · Granted Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11952600

PH20 polypeptide variants, formulations and uses thereof

HALOZYME, INC. · Granted Tue Apr 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11951100

Formulations of RBP4 inhibitors and methods of use

Belite Bio, Inc · Granted Tue Apr 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11938177

Peptide vaccine formulations and use thereof for inducing an immune response

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Mar 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11939346

Preparation of psilocybin, different polymorphic forms, intermediates, formulations and th

Compass Pathfinder Limited · Granted Tue Mar 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11931421

Muscle targeting complexes and formulations for treating myotonic dystrophy

Dyne Therapeutics, Inc. · Granted Tue Mar 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11931328

Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives

AMNEAL PHARMACEUTICALS LLC · Granted Tue Mar 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11931354

Formulations of oxabicycloheptanes and oxabicycloheptenes

Lixte Biotechnology, Inc. · Granted Tue Mar 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11925626

Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin

Corcept Therapeutics Incorporated · Granted Tue Mar 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted